Here, we propose that targeting BAG1 or BAG3 or other specific ubiquitin-regulators, such as USP9X, may emerge as a novel therapeutic approach to inhibit AML by reducing elevated apoptotic threshold. Here, USP9X is linked to acute myeloid leukemia.